The effect of bopindolol on lipids and platelet aggregation.
An open ambulatory study was performed to assess the effect of bopindolol in 19 hypertensive patients (W.H.O. stage I-II). A statistically significant decrease in systolic and diastolic pressure as well as heart rate (never below 60 beats per minute) was demonstrated. No undesirable subjective side-effects of the drug were reported. Compared with the serum concentrations after placebo, a decrease in all low-density fractions was observed after 12 months. The total cholesterol/HDL cholesterol ratio did not deteriorate and the apolipoprotein A/apolipoprotein B ratio increased. The values of triacylglycerols during 8 months of therapy did not exceed initial serum concentrations following placebo administration. Patients treated with bopindolol exhibited decreased platelet aggregation due to collagen.